511544-99-3

Upstream product

• 79640-70-3 (S)-5-(tert-butoxy)-4-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-5-oxopentanoic acid 
• 167986-15-4 N-[1,1-bis(hydroxymethyl)-2-[(1-oxohexadecyl)oxy]ethyl]glycinamide 
• 79640-72-5 L-glutamic acid 1-tert-butyl ester 5-methyl ester 
• 19741-14-1 4-[(2,4-diaminopteridin-6-ylmethyl)methylamino]benzoic acid 
• 511544-85-7 α-tert-butyl N-[4-(N-benzyloxycarbonyl-N-methyl)aminobenzoyl]-L-glutamate 
• 511544-87-9 α-tert-butyl-N-[4-(methylamino)benzoyl]-L-glutamate 
• 2528-30-5 4-<<(benzyloxy)carbonyl>methylamino>benzoic acid 
• 45120-30-7 L-glutamic acid α-tert-butyl ester 
• 79648-88-7 α-tert-butyl γ-methyl N'-<4--N-methylamino>benzoyl>-L-glutamate 
• 66891-86-9 benzyl (4-(chlorocarbonyl)phenyl)(methyl)carbamate 

Relevant academic research and scientific papers

The use of Tris-lipidation to modify drug cytotoxicity in multidrug resistant cells expressing P-glycoprotein or MRP1

1. Increasing the lipophilicity is a strategy often used to improve a compound's cellular uptake and retention but this may also convert it into a substrate for an ATP-dependent transporter such as P-glycoprotein or the multidrug resistance-associated pro

Total synthesis of methotrexate-γ-TRIS-fatty acid conjugates

Several routes for the regiospecific synthesis of lipophilic γ-conjugates of methotrexate are described. Coupling of methotrexate-α-tert-butyl ester with glycyl-TRIS-(mono-/di-/tri-)palmitate followed by trifluoroacetic acid cleavage of the α-protection a